All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL
Featured
Bookmark this article
During the 17th ICML, the Lymphoma Hub spoke with Georg Lenz, Münster University Hospital, Münster, DE. We asked for a summary of Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) vs R-CHOEP (cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and etoposide) treatment in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). Lenz highlights the efficacy and safety data of each treatment for this population of patients.
Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox